Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers identify genetic markers to predict response to chemotherapy for colorectal cancer

07.06.2004


One of the most common challenges facing oncologists today is determining the best course of treatment for their patients - one that would be effective and have the fewest possible side effects. In a study presented today at the 40th Annual Meeting of the American Society of Clinical Oncology in New Orleans, Fox Chase Cancer Center researchers have identified genetic markers in the blood that can help predict a patient’s response to and side effects from irinotecan, a common chemotherapy drug for colorectal cancer.



Leslie E. Carlini, Ph.D., a research associate in the Fox Chase laboratory of Rebecca L. Blanchard, Ph.D., presented the findings. Their research focuses on genetic variations that influence the effect of medicines on different people - an area of study called pharmacogenetics. Ultimately, the goal is to improve the way drugs are prescribed by identifying individuals who are likely to benefit from a specific medicine or who are at increased risk of serious side effects.

"Our data suggest that variations in genes that help metabolize irinotecan may be useful predictors of how well colorectal cancer patients respond to this drug and how severe side effects will be," Carlini said.


To see how genetic variations affected response and side effects, the laboratory analyzed DNA in blood samples taken during a multi-site clinical trial to test an investigational combination chemotherapy regimen for metastatic colorectal cancer. The patients received intravenous irinotecan once a week and twice-daily tablets of the drug capecitabine for two weeks of a three-week treatment cycle.

The researchers looked at a family of genes called UGTs (UDP-glucuronosyltransferases), involved in breaking down irinotecan within the body and ultimately disposing of it. "Our research indicates that patients specific UGT1A7 or UGT1A9 genotypes will get more anti-tumor response from the chemotherapy combination. What’s more, these patients should have fewer side effects," Carlini said.

There were no statistically significant associations between the other two UGT genes and either side effects or antitumor response. "In reality, physicians will soon be able to personalize cancer therapies based on the tumor’s characteristics and the genetic profile of the person," said Carlini. "The ultimate goal is to tailor treatment that offers the most anti-tumor activity with the fewest side effects."

In a separate study based on the same clinical trial, Fox Chase researchers also discovered a protein marker to help predict response to combination chemotherapy with capecitabine and irinotecan. Medical oncologist Neal J. Meropol will present these results at the ASCO annual meeting in a Gastrointestinal (Colorectal) Cancer Session on Sunday, June 6 between 8 a.m. and 12 noon (Abstract # 3520, Poster #11).

In addition to Blanchard and Meropol, Carlini’s colleagues in the study include Y.-M. Chen, Ph.D., T. Hill, and C. McGarry of Roche Labs, Nutley, N.J.; and P. J. Gold, M.D., of the Swedish Cancer Institute, Seattle, Wash.


Fox Chase Cancer Center was founded in 1904 in Philadelphia, Pa., as the nation’s first cancer hospital. In 1974, Fox Chase became one of the first institutions designated as a National Cancer Institute Comprehensive Cancer Center. Fox Chase conducts basic, clinical, population and translational research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center’s web site at www.fccc.edu or call 1-888-FOX CHASE.

Karen C. Mallet | EurekAlert!
Further information:
http://www.fccc.edu/
http://www.fccc.edu

More articles from Studies and Analyses:

nachricht Europe’s Demographic Future. Where the Regions Are Heading after a Decade of Crises
10.08.2017 | Berlin-Institut für Bevölkerung und Entwicklung

nachricht Scientists reveal source of human heartbeat in 3-D
07.08.2017 | University of Manchester

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Nagoya physicists resolve long-standing mystery of structure-less transition

21.08.2017 | Materials Sciences

Chronic stress induces fatal organ dysfunctions via a new neural circuit

21.08.2017 | Health and Medicine

Scientists from the MSU studied new liquid-crystalline photochrom

21.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>